Published • loading... • Updated
Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
- Insilico Medicine, a clinical-stage drug discovery company using generative AI, will be included in the HKEX Tech 100 Index to highlight opportunities across the AI value chain.
- The HKEX Tech 100 Index tracks 100 major Hong Kong-listed companies with high exposure to key technology themes, eligible for Southbound Stock Connect.
- Inclusion in the index demonstrates Insilico Medicine's AI-driven advancements in healthcare and strengthens its technological credibility.
- Insilico Medicine reported approximately $106 million in revenue in the first half of 2026, a 287% increase year-over-year, and achieved an adjusted net profit of over $51 million.
Insights by Ground AI
40 Articles
40 Articles
Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
CAMBRIDGE, Mass., Sept. 2, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced that it will be included in the HKEX Tech 100 Index, following the methodology enhancements to…
·Indiana, United States
Read Full ArticleCoverage Details
Total News Sources40
Leaning Left4Leaning Right4Center27Last UpdatedBias Distribution77% Center
Bias Distribution
- 77% of the sources are Center
77% Center
12%
C 77%
11%
Factuality
To view factuality data please Upgrade to Premium
